Cingulate Q2 2026 net loss widens to $5.9 million; cash $28.4 million
Cingulate reported a second-quarter 2026 net loss of $5.9 million, up from $5.0 million a year earlier, as selling, general and administrative expenses rose 101.5% to $3.9 million on commercial readiness spending. The company said its $28.4 million in cash as of June 30, 2026 should fund operations into mid-2027, but the FDA issued a Complete Response Letter for CTx-1301 on June 1, 2026, and resubmission of the NDA depends on finishing manufacturing work.
Key points
- Q2 2026 net loss was $5.9 million, compared with $5.0 million in Q2 2025
- SG&A expenses were $3.9 million, up 101.5%, driven by commercial readiness build-out
- R&D expenses fell 44.9% to $1.5 million in the quarter
- Cash and cash equivalents were $28.4 million at June 30, 2026, with runway into mid-2027
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.